Valeant Puts Up $250M For Struggling Solta Medical

Law360, New York (December 16, 2013, 4:04 PM EST) -- Valeant Pharmaceuticals International Inc. will buy cosmetics and body care company Solta Medical Inc. for about $250 million, the companies said Monday, in a deal that enables Valeant to add Solta's energy-based medical devices to its device portfolio.

The deal, which is expected to close in the first quarter of 2014, will see Valeant acquire all of the outstanding common stock of Solta for about $2.92 per share, all in cash, which represents a 40 percent premium to the company's closing share price on Dec. 13....
To view the full article, register now.